Drug profile · INN
exenatide synthetic
BYETTA
exenatide synthetic (BYETTA) is a glucagon-like peptide 1 receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — exenatide synthetic
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
exenatide synthetic (BYETTA) is a glucagon-like peptide 1 receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucagon-like peptide 1 receptor agonist
Primary target: Glucagon-like peptide 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is exenatide synthetic?
exenatide synthetic (BYETTA) is a glucagon-like peptide 1 receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for exenatide synthetic?
BYETTA is a marketed brand name for exenatide synthetic. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of exenatide synthetic?
exenatide synthetic has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.